Harrison.ai vs Pearl

Harrison.ai, the company behind Annalise, sells chest X-ray, head CT and chest CT reading to hospitals, emergency departments and teleradiology services. NHS Grampian figures in a Scottish Health Technologies Group summary give sensitivity of 78%, specificity of 91%, positive predictive value of 3% and negative predictive value of 99.99%. A Radiology study of 5,235 patients found Annalise Enterprise CXR v3.8 and six other devices all produced more false positives than radiologist reports. Annalise shows nine openFDA decisions, from CXR Triage Pneumothorax in February 2022 to Annalise Enterprise in March 2026 (applicant Harrison-AI Medical Pty, Ltd.), while press coverage says twelve.

Pearl reads dental radiographs, and a hospital radiology department and a dental practice do not buy the same product. Second Opinion has eight openFDA decisions, from March 2022 to November 2025, and marks up to 18 findings per image on bitewing, periapical and panoramic films. Pearl is for a dental support organization standardizing reads across offices. Annalise is for an emergency department with chest films and head CTs.